A Q & A with Visiting Professor Matthew Rimmer on the Trans-Pacific Partnership

Thursday, October 8, 2015
visiting professor matthew rimmer

Distinguished Visiting Professor Matthew Rimmer researches and teaches intellectual property and innovation law at the Queensland University of Technology (QUT) in Brisbane, Australia, and was named one of Managing IP's 50 most influential intellectual property people in 2014. At the Faculty of Law this fall, he taught the intensive course, The Trans-Pacific Partnership: Intellectual Property and Trade. Nexus executive editor Lucianna Ciccocioppo interviewed Prof.

Doctoral work at U of T yields three new books on international and comparative law

Tuesday, July 28, 2015

Three new books by recent doctoral graduates of the University of Toronto Faculty of Law, developed from their dissertations and published by major academic presses, showcase the importance of the international and comparative law research conducted by students in the doctoral program.

"These three books show the caliber of the students recruited into our doctoral program, and the hard work that we put into providing them with the skills needed to make all their talents flourish," says Prof. Mariana Mota Prado, associate dean, graduate program.

Prof. David Schneiderman writes "Where is Canada’s national debate over trade dispute panels?" in Globe and Mail

Saturday, June 13, 2015

In a commentary in the Globe and Mail, Prof. David Schneiderman examines why there is no debate in Canada about investor-state dispute settlement mechanisms in free trade deals, unlike in the United States, despite their impact on the actions of Canadian governments ("Where is Canada’s national debate over trade dispute panels?", June 12, 2015).

Innovation Law & Policy Workshop: Rochelle Dreyfuss

INNOVATION LAW & POLICY WORKSHOP

presents

Rochelle Dreyfuss

New York University School of Law

Economic Espionage as Reality or Rhetoric: Equating Trade Secrecy with National Security

Co-Authored with Orly Lobel, University of San Diego, School of Law

 

Presidential Elections in Brazil: a choice of development models

Yesterday, Brazil decided to re-elect its President, keeping Dilma Rousseff for another 4 years in power. The margin of victory was really small (51.6%). The wealthy regions (south and southeast) have largely favoured Dilma's opponent, Aecio Neves, while the poorest regions (north and northeast) have strongly supported Dilma.

While the elections clearly show a divided country, those who have followed the debates and scrutinized the policy proposals know that the results reflect more than a division based on income levels. The outcome of this election shows a country divided over two very different development projects. 

Food security about entitlement, not availability, says scholar Anne Orford, Katherine Baker Memorial lecturer

Tuesday, September 23, 2014
portrait of Melcourne Law School professor Anne Orford

By Peter Boisseau

The wave of protests called the “Arab Spring” were as much about bread as freedom, says Melbourne Law School Professor Anne Orford, and brought into sharp focus a “dark side” of free trade principles lawyers helped create two centuries ago and now could help solve.

Getting into UofT Law - JD Admissions

JD Admissions visits UofT Department of Criminology

JD AdmissionsGet the inside scoop on applying to our JD program directly from the Faculty of Law Admissions Office and hear from current law students. 

Learn about our whole-person admission process and how to improve your application to our JD program. 

Innovation Law & Policy Workshop: Ruth Okediji

INNOVATION LAW & POLICY WORKSHOP

presents

Ruth Okediji

University of Minnesota Law School 

Presentation Title:

Legal Innovation in International Intellectual Property Relations: Revisiting Twenty Years of the TRIPS Agreement

 

Wednesday, October 1, 2014

European Medicines Agency's Proposed Data Release Policy: Promoting Pharma's Control Over Data

[Note: this Blog was originally written for and appeared as Guest Blog in PLoS' Blog "Speaking Of Medicine" (May 30, 2014) Reproduced here with permission]

Things were looking good recently in Europe for data transparency, a necessary, albeit not sufficient, tool to promote integrity of pharmaceutical data. The European Court’s Vice-President overturned in November 2013 two lower court interim suspensions of EMA’s data access decision in relation to Abbvie’s drug Humira and Intermune’s Esbriet, which had stalled EMA’s data release approach. Shortly after, Abbvie withdrew the Humira lawsuit. Then in April 2014, the European Parliament approved the new Clinical Trials Regulation that introduced a requirement to register all clinical trials and make all clinical study reports in relation to EMA approved drugs publicly available. These developments put EMA again in the driver’s seat for the further implementation of its promised prospective data release policy.

Pages